Literature DB >> 2766417

Synthesis and antitumor activity of a novel water soluble mitomycin analog; 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C.

M Kono, Y Saitoh, M Kasai, A Sato, K Shirahata, M Morimoto, T Ashizawa.   

Abstract

Introducing the mercaptoethyl group at the 7-N position of mitomycin C 1 has led to the isolation of 7-N,7'-N'-dithiodiethylenedimitomycin C 2. The compound 2 showed excellent antitumor activity against sarcoma 180 (sc-ip) and leukemia P388 (ip-ip) in mice. As an extension of this study, we synthesized mitomycin dimers with symmetrical disulfide and mitomycin derivatives with unsymmetrical disulfide at the 7-N side chain. Among these compounds, the water soluble conjugate 3 with ethyl gamma-L-glutamyl-L-cysteinylglycinate was far more effective against sarcoma 180 and leukemia P388 than 1. During the subsequent stage of inquiry for the potent congeners of 3, the compound 4 (water solubility: greater than 500 mg/ml), designated as KW2149, with the gamma-L-glutamylcystamino group at the 7th position was finally selected for further evaluation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2766417     DOI: 10.1248/cpb.37.1128

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  7 in total

1.  Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.

Authors:  T Tsuruo; Y Sudo; N Asami; M Inaba; M Morimoto
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Disposition and metabolism of KW-2149, a novel anticancer agent.

Authors:  S Kobayashi; J Ushiki; K Takai; S Okumura; M Kono; M Kasai; K Gomi; M Morimoto; H Ueno; T Hirata
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C.

Authors:  E Kobayashi; M Okabe; M Kono; H Arai; M Kasai; K Gomi; J H Lee; M Inaba; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.

Authors:  T Bando; K Kasahara; K Shibata; Y Numata; U Heki; H Shirasaki; K Iwasa; M Fujimura; T Matsuda
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

5.  Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion.

Authors:  L Dirix; G Catimel; R Verdonk; E De Bruijn; B Tranchand; C Ardiet; A Van Oosterom
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

6.  Effects and systemic uptake of the new mitomycin C analogue KW-2149 in beagle dogs after intravesical administration.

Authors:  M Sorber; E A De Bruijn; M Kockx; J Bultinck; A T Van Oosterom; L Denis
Journal:  Urol Res       Date:  1995

7.  Establishment and characterization of non-small cell lung cancer cell lines resistant to mitomycin C under aerobic conditions.

Authors:  K Shibata; K Kasahara; T Bando; Y Nakatsumi; M Fujimura; T Tsuruo; T Matsuda
Journal:  Jpn J Cancer Res       Date:  1995-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.